These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Mast cell and cancer with special emphasis on il-37 an anti-inflammatory and inhibitor of innate immunity: new frontiers. Carinci F; Lessiani G; Spinas E; Kritas SK; Ronconi G; Caraffa Al; Conti P J Biol Regul Homeost Agents; 2016; 30(4):945-950. PubMed ID: 28078840 [TBL] [Abstract][Full Text] [Related]
6. Potential therapeutic use of IL-37: a key suppressor of innate immunity and allergic immune responses mediated by mast cells. Conti P; Carinci F; Lessiani G; Spinas E; Kritas SK; Ronconi G; Caraffa A; Theoharides TC Immunol Res; 2017 Oct; 65(5):982-986. PubMed ID: 28748328 [TBL] [Abstract][Full Text] [Related]
10. Mast cells as effector cells of innate immunity and regulators of adaptive immunity. Cardamone C; Parente R; Feo GD; Triggiani M Immunol Lett; 2016 Oct; 178():10-4. PubMed ID: 27393494 [TBL] [Abstract][Full Text] [Related]
11. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy. Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Ronconi G J Biol Regul Homeost Agents; 2020; 34(6):1971-1975. PubMed ID: 33016027 [TBL] [Abstract][Full Text] [Related]
12. Microglia and mast cells generate proinflammatory cytokines in the brain and worsen inflammatory state: Suppressor effect of IL-37. Conti P; Lauritano D; Caraffa A; Gallenga CE; Kritas SK; Ronconi G; Martinotti S Eur J Pharmacol; 2020 May; 875():173035. PubMed ID: 32097657 [TBL] [Abstract][Full Text] [Related]
13. Progression in migraine: Role of mast cells and pro-inflammatory and anti-inflammatory cytokines. Conti P; D'Ovidio C; Conti C; Gallenga CE; Lauritano D; Caraffa A; Kritas SK; Ronconi G Eur J Pharmacol; 2019 Feb; 844():87-94. PubMed ID: 30529470 [TBL] [Abstract][Full Text] [Related]
14. Activated Mast Cells Mediate Low-Grade Inflammation in Type 2 Diabetes: Interleukin-37 Could Be Beneficial. Conti P; Ronconi G; Kritas SK; Caraffa A; Theoharides TC Can J Diabetes; 2018 Oct; 42(5):568-573. PubMed ID: 29885882 [TBL] [Abstract][Full Text] [Related]
15. Mast cells emerge as mediators of atherosclerosis: Special emphasis on IL-37 inhibition. Conti P; Lessiani G; Kritas SK; Ronconi G; Caraffa A; Theoharides TC Tissue Cell; 2017 Jun; 49(3):393-400. PubMed ID: 28420489 [TBL] [Abstract][Full Text] [Related]
16. Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion. Woolley DE; Tetlow LC Arthritis Res; 2000; 2(1):65-74. PubMed ID: 11219391 [TBL] [Abstract][Full Text] [Related]
17. Mast Cell Cytokines IL-1, IL-33, and IL-36 Mediate Skin Inflammation in Psoriasis: A Novel Therapeutic Approach with the Anti-Inflammatory Cytokines IL-37, IL-38, and IL-1Ra. Conti P; Pregliasco FE; Bellomo RG; Gallenga CE; Caraffa A; Kritas SK; Lauritano D; Ronconi G Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360845 [TBL] [Abstract][Full Text] [Related]
18. IL-10-overexpressing B cells regulate innate and adaptive immune responses. Stanic B; van de Veen W; Wirz OF; Rückert B; Morita H; Söllner S; Akdis CA; Akdis M J Allergy Clin Immunol; 2015 Mar; 135(3):771-80.e8. PubMed ID: 25240783 [TBL] [Abstract][Full Text] [Related]
19. New concepts in neuroinflammation: mast cells pro-inflammatory and anti-inflammatory cytokine mediators. Caraffa Al; Conti C; D Ovidio C; Gallenga CE; Tettamanti L; Mastrangelo F; Ronconi G; Kritas SK; Conti P J Biol Regul Homeost Agents; 2018; 32(3):449-454. PubMed ID: 29921369 [TBL] [Abstract][Full Text] [Related]